SEATTLE, July 22, 2021, (MEDGADGET) — Global Postpartum Depression Drug Market Analysis
Overview
PPD, commonly referred to as postpartum depression, is a form of mood illness that occurs after a pregnancy. Insomnia, exhaustion, and melancholy are all symptoms of depression, as are lack of appetite, mood swings, worry, and hostility. Hormonal abnormalities in females, such as high prolactin, reduced oxytocin, and thyroid hormone levels, might induce PPD.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2258
Drivers
The global postpartum depression drug market is projected to develop at a faster rate than the overall market during the forecast period due to increased research activity for the treatment of PPD. Sage Therapeutics is now conducting a phase 3 clinical trial for the medication Brexanolone, which may be effective in the treatment of PPD. The research began in May 2018 and is expected to be finished in September 2020.
In addition, Marinus Pharmaceuticals is now conducting a clinical phase 2 trial for the medication Ganaxolone in the treatment of PPD and other mood disorders. The research trial began in June 2017 and is scheduled to end in June 2019.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2258
Restraint
Antidepressant medication rejections by the U.S. Food and Drugs Administration (US FDA) are projected to be a key stumbling block to the global postpartum depression drug market’s growth throughout the forecast period. The US FDA denied Alkermes plc.’s medicine candidate ALKS 5461, which is to be taken orally, a New Drug Application in April 2018. The medicine may be beneficial in the treatment of depressive disorders that are resistant to conventional treatments. This refusal was owing to the oral medication’s ineffectiveness.
Regional Insights
Due to rising awareness of PPD, North America is expected to dominate the global postpartum depression drug market over the forecast period. May 2017 is designated as National Maternal Depression Awareness Month in the U.S., emphasizing the significance of anxiety during and after pregnancy.
Moreover, due to the rising frequency of PDD in Asia Pacific, the global postpartum depression drug market is projected to rise significantly over the projected period. As per a World Health Organization (WHO) research from July 2018, 22 percent of Indian women suffer with PPD on an annual basis.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2258
Competitive Landscape
Major companies contributing in the global postpartum depression drug market are Cipla Limited, Sun Pharmaceutical Industries Ltd., Anikem Laboratories, Sage Therapeutics Inc., Shionogi & Co., Ltd., Mylan N.V., and Intas Pharmaceuticals Ltd.
Table of Content
Global Postpartum Depression Drug Market Research Report
Section 1: Global Postpartum Depression Drug Industry Overview
Section 2: Global Economic Impact on Postpartum Depression Drug Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Postpartum Depression Drug Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Postpartum Depression Drug Market Forecast
Have a Look at Related Research Insights:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837